Neuberg Sehgal Path Lab has expanded its diagnostic portfolio with the launch of advanced cytogenetics testing in Mumbai. With this expansion, the laboratory brings high-end chromosomal analysis closer to patients, enabling more accurate diagnosis, risk assessment, and personalised treatment planning.

Cytogenetics is a specialised diagnostic discipline that examines chromosomal structure and behaviour to identify genetic abnormalities associated with inherited disorders and malignancies. Neuberg Sehgal Path Lab’s new offering integrates two globally established techniques, Fluorescent In-Situ Hybridisation (FISH) and Conventional Karyotyping, to detect chromosomal alterations such as translocations, deletions, and insertions.

Until now, cytogenetics testing in India has largely been limited to select large institutional centres such as Tata Memorial Hospital, CMC Vellore, and SGPGI Lucknow. Neuberg Sehgal Path Lab is among the few standalone diagnostic laboratories to introduce this capability, expanding access to advanced genetic testing within a comprehensive diagnostic ecosystem.

Enabling Precision in Cancer and Prenatal Care

The availability of cytogenetics testing plays a critical role in both prenatal screening and oncology diagnostics. Prenatal care supports the early identification of chromosomal disorders such as Down syndrome. In oncology, it aids in diagnosing and classifying blood cancers including acute promyelocytic leukaemia (APML) and Burkitt’s lymphoma, while also helping clinicians assess prognosis and therapeutic intensity.

One of the key advantages of this technology is its role in cancer risk stratification, allowing physicians to tailor treatment strategies, ranging from aggressive chemotherapy to more conservative regimens, based on a patient’s genetic profile.

Faster Results, Greater Accessibility

FISH testing offers rapid insights with results typically available within three days, while conventional karyotyping provides a more comprehensive chromosomal overview with a turnaround time of approximately two weeks. Importantly, cytogenetics remains a cost-effective alternative to many advanced molecular genetic tests, making it accessible to a broader patient population.

Given the complexity and labour-intensive nature of cytogenetics, Neuberg Sehgal Path Lab has established a dedicated team of specialists led by Dr Simpy Raj, Consultant Hematopathologist and Cytogeneticist, along with Dr Prerna, Senior Scientific Officer, who brings extensive experience in cytogenetic analysis and interpretation.

Strengthening Integrated Diagnostics

Commenting on the launch, Dr Kunal Sehgal, Managing Director and Chief Pathologist, Neuberg Sehgal Path Lab, highlighted the clinical impact of the initiative, noting that the addition of cytogenetics significantly enhances diagnostic accuracy for blood cancers while ensuring affordability and timely reporting.

Also read: China Halts Import and Sale of Sun Pharma’s Dementia Drug Over Quality Concerns

With this launch, Neuberg Sehgal Path Lab further strengthens its integrated diagnostic capabilities, offering cytogenetics, bone marrow evaluation, flow cytometry, and molecular testing under one roof. The expansion reflects the laboratory’s commitment to delivering advanced, patient-centric diagnostics supported by specialised expertise and cutting-edge technology.

Cytogenetics testing is recommended for individuals undergoing prenatal screening, patients diagnosed with specific cancers, and those requiring detailed genetic risk assessment, reinforcing its growing importance in modern, precision-driven healthcare.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!